Before propensity score matching, differences could be observed between the sorafenib and lenvatinib groups regarding the Barcelona Clinic liver cancer stage, prothrombin, alpha fetoprotein, and blood urea nitrogen levels. This evidence concerns the gene AFP and liver cancer.